The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thijs, L. G.
Right arrow Articles by Wagstaff, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thijs, L. G.
Right arrow Articles by Wagstaff, J.

The Journal of Immunology, Vol 144, Issue 6 2419-2424, Copyright © 1990 by American Association of Immunologists

ARTICLES

Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects

LG Thijs, CE Hack, RJ Strack van Schijndel, JH Nuijens, GJ Wolbink, AJ Eerenberg-Belmer, H Van der Vall and J Wagstaff
Medical Intensive Care Unit, Free University Hospital, Amsterdam, The Netherlands.

Therapy with high doses of rIL-2 is complicated by the occurrence of hypotensive reactions and the development of a vascular leakage syndrome (VLS). In four patients, who together received seven cycles of high doses of IL-2 (up to 12 x 10(6) U per m2 per day), and who developed these side effects, we observed an unexpected increase in plasma levels of C3a, indicating activation of the complement system. C3a levels markedly increased during IL-2 therapy from 4 nmol/liter (mean level) before therapy to 23 nmol/liter at the end of the cycle. Activation of C3 occurred via the classical pathway inasmuch as C4a levels also increased during therapy. Mean daily C3a levels correlated with signs of the VLS, such as daily weight gain (p less than 0.001) and albumin levels (inverse correlation, p less than 0.001). In five additional patients, who together received seven cycles of lower doses of IL-2 (2 x 10(6) U per m2 per day) and who did not develop a VLS, only moderate increases in C3a levels (up to 13 nmol/liter) were observed. The highest levels at the first day of the regimen (mean: 7 nmol/liter) occurred 8 h after the IL-2 infusion. Thus, administration of IL-2 induces a dose-dependent activation of the complement system in vivo, which appeared to be related to the development of side effects of this therapy, such as the VLS.


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
A Familian, A E Voskuyl, G J van Mierlo, H A Heijst, J W R Twisk, B A C Dijkmans, and C E Hack
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis
Ann Rheum Dis, July 1, 2005; 64(7): 1003 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack
C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema
Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Schmidt, H.-J. Hertfelder, T. von Spiegel, R. Hering, M. Harzheim, H. Lassmann, M. Deckert-Schluter, and U. Schlegel
Lethal capillary leak syndrome after a single administration of interferon beta-1b
Neurology, July 1, 1999; 53(1): 220 - 220.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
A. Q. Rafi, A. Zeytun, M. J. Bradley, D. P. Sponenberg, R. L. Grayson, M. Nagarkatti, and P. S. Nagarkatti
Evidence for the Involvement of Fas Ligand and Perforin in the Induction of Vascular Leak Syndrome
J. Immunol., September 15, 1998; 161(6): 3077 - 3086.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Citarella, A. Felici, M. Brouwer, J. Wagstaff, A. Fantoni, and C. E. Hack
Interleukin-6 Downregulates Factor XII Production by Human Hepatoma Cell Line (HepG2)
Blood, August 15, 1997; 90(4): 1501 - 1507.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. Rabinovici, G. Feuerstein, F. Abdullah, M. Whiteford, P. Borboroglu, E. Sheikh, D.-R. Phillip, P. Ovadia, L. Bobroski, O. Bagasra, et al.
Locally Produced Tumor Necrosis Factor-{alpha} Mediates Interleukin-2Induced Lung Injury
Circ. Res., February 1, 1996; 78(2): 329 - 336.
[Abstract] [Full Text]

Home page
 Arch SurgHome page
M. A. Boermeester, P. A. M. van Leeuwen, S. M. Coyle, G. J. Wolbink, C. E. Hack, and S. F. Lowry
Interleukin-1 Blockade Attenuates Mediator Release and Dysregulation of the Hemostatic Mechanism During Human Sepsis
Arch Surg, July 1, 1995; 130(7): 739 - 748.
[Abstract] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
G. L. Clayman, F. J. Liu, H. E. Savage, D. L. Taylor, P. Lavedan, R. M. Buchsbaum, C. Pellegrino, J. M. Trujillo, G. Young, and S. P. Schantz
Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa
Arch Otolaryngol Head Neck Surg, January 1, 1992; 118(1): 41 - 48.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1990 by The American Association of Immunologists, Inc. All rights reserved.